Skip to main content

Table 2 Enriched KEGG pathways and GO:BP categories among the genes increased by EPO and inhibited by LIF at 20 h

From: Leukemia inhibitory factor inhibits erythropoietin-induced myelin gene expression in oligodendrocytes

Category

Term

Fold enrichment

Gene symbols

P value

KEGG

Fat digestion and absorption

87.7

Pnlip, CD36, RGD1565355

3.4E-04

KEGG

Adipocytokine signaling pathway

44.5

CD36, Ppargc1a, RGD1565355

1.3E-03

GO:BP

Intestinal cholesterol absorption

730.6

PnlipP, CD36

2.5E-03

KEGG

Insulin resistance

30.3

CD36, Ppargc1a, RGD1565355

2.9E-03

GO:BP

Response to drug

11.1

CD36, Plin2, Htr2c, PPARGC1A

3.7E-03

KEGG

AMPK signaling pathway

26.3

CD36, PPARGC1A, RGD1565355

3.8E-03

GO:BP

Cell surface receptor signaling pathway

22.8

Calcr, CD36, RGD1565355

6.1E-03

GO:BP

Long-chain fatty acid transport

243.5

CD36, Plin2

7.5E-03

GO:BP

Fatty acid oxidation

182.7

CD36, Ppargc1a

1.0E-02

GO:BP

Lipid storage

108.2

CD36, Plin2

1.7E-02

GO:BP

Response to lipid

97.4

Pnlip, CD36

1.9E-02

GO:BP

Receptor internalization

69.6

Calcr, CD36

2.6E-02

KEGG

Malaria

37.7

CD36, RGD1565355

4.5E-02

  1. DAVID Functional Annotation Chart analysis showing the overrepresented GO:BP categories and KEGG pathways among the genes increased by EPO and decreased by LIF at 20 h. The fold enrichment and the significance of enrichment (P value) are reported